Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[18F]MNI-815 PET Imaging in Tauopathies
NCT02531360Phase 1Completed
- Sponsor
- Molecular NeuroImaging
- Start
- May 2015
- Primary completion
- Jul 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of [18F]MNI-815 in Alzheimer's disease (AD), progressive supranuclear palsy (PSP), Corticobasal Syndrome (CBS) and 1 more, sponsored by Molecular NeuroImaging. Primary endpoint: Brain uptake of [18F]MNI-815 at Day 1. Started May 2015; status: completed.
02
Drugs
[18F]MNI-815
03
Conditions
Alzheimer's disease (AD)progressive supranuclear palsy (PSP)Corticobasal Syndrome (CBS)frontotemporal dementia (FTD)
Beyond the preview
Go deeper on NCT02531360.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02531360.